Clinical pharmacology of tyrosine kinase inhibitors becoming generic drugs: the regulatory perspective

Over the last decades, billions have been spent and huge efforts have been taken in basic and clinical cancer research [CA Cancer J Clin 63: 11-30]. About a decade ago, the arms race between drugs and cancer cells reached a new level by introduction of tyrosine kinase inhibitors (TKI) into pharmacol...

Descripción completa

Detalles Bibliográficos
Autores principales: Eckstein, Niels, Röper, Lea, Haas, Bodo, Potthast, Henrike, Hermes, Ulrike, Unkrig, Christoph, Naumann-Winter, Frauke, Enzmann, Harald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922331/
https://www.ncbi.nlm.nih.gov/pubmed/24502453
http://dx.doi.org/10.1186/1756-9966-33-15

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922331/
https://www.ncbi.nlm.nih.gov/pubmed/24502453
http://dx.doi.org/10.1186/1756-9966-33-15

Ejemplares similares